Profile data is unavailable for this security.
About the company
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
- Revenue in JPY (TTM)2.88tn
- Net income in JPY15.64bn
- Incorporated1925
- Employees49.58k
- LocationTakeda Pharmaceutical Co Ltd4F, 2-1-1, Nihombashihon-choCHUO-KU 103-8668JapanJPN
- Phone+81 332782111
- Fax+81 332782000
- Websitehttps://www.takeda.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck KGaA | 1.88tn | 137.26bn | 1.85tn | 54.04k | 45.27 | 2.91 | 5.27 | 0.9802 | 2.62 | 7.96 | 35.98 | 41.76 | 0.4025 | 1.94 | 4.86 | 302,786.50 | 2.96 | 4.54 | 3.90 | 5.98 | 63.13 | 66.09 | 7.35 | 11.03 | 1.08 | 5.40 | 0.4083 | 9.90 | 2.20 | 5.98 | -57.97 | -2.28 | 14.48 | 5.64 |
| Shionogi & Co Ltd | 356.40bn | 126.48bn | 2.13tn | 5.23k | 16.59 | 3.04 | 14.69 | 5.98 | 405.18 | 405.18 | 1,141.93 | 2,208.95 | 0.4679 | 1.44 | 7.66 | 68,105,300.00 | 16.61 | 13.21 | 18.43 | 15.07 | 83.71 | 77.72 | 35.49 | 26.76 | 6.31 | -- | 0.0011 | 26.56 | 5.53 | 4.65 | 21.95 | 26.73 | -12.11 | 15.36 |
| Alexion Pharmaceuticals, Inc. | 516.87bn | 148.51bn | 2.58tn | 2.66k | 17.72 | 2.28 | 13.56 | 5.00 | 6.04 | 6.53 | 21.07 | 46.85 | 0.3305 | 0.747 | 4.67 | 1,782,982.00 | 9.50 | 3.24 | 10.25 | 3.51 | 92.04 | 90.43 | 28.73 | 10.96 | 3.45 | 23.89 | 0.2013 | 0.00 | 16.34 | 21.64 | -95.69 | -39.15 | 48.67 | -- |
| Otsuka Holdings Co Ltd | 1.37tn | 116.33bn | 2.70tn | 32.94k | 23.28 | 1.52 | 14.23 | 1.97 | 208.24 | 208.24 | 2,532.43 | 3,189.11 | 0.5289 | 2.70 | 3.74 | 41,677,970.00 | 4.63 | -- | 5.68 | -- | 67.28 | -- | 8.75 | -- | 1.95 | -- | 0.1572 | -- | 4.20 | -- | -26.67 | -- | -- | -- |
| Astellas Pharma Inc | 1.31tn | 246.93bn | 3.57tn | 16.24k | 14.55 | 2.75 | 11.52 | 2.72 | 129.85 | 129.85 | 689.28 | 687.45 | 0.6774 | 1.93 | 3.98 | 80,633,010.00 | 12.77 | 10.34 | 16.82 | 13.43 | 78.06 | 75.90 | 18.85 | 14.30 | 1.46 | -- | 0.1135 | 37.46 | 0.4639 | 2.76 | 34.97 | 19.59 | -1.47 | 7.07 |
| Chugai Pharmaceutical Co Ltd | 662.20bn | 139.54bn | 5.95tn | 7.43k | 41.77 | 7.16 | -- | 8.99 | 254.58 | 254.58 | 1,208.13 | 1,485.30 | 0.6912 | 1.62 | 3.58 | 89,100,910.00 | 14.57 | 8.40 | 17.35 | 9.93 | 59.25 | 52.32 | 21.08 | 13.07 | 2.80 | -- | 0.00 | 50.53 | 8.53 | 6.48 | 27.20 | 12.69 | 39.01 | 9.86 |
| Takeda Pharmaceutical Co Ltd | 2.88tn | 15.64bn | 6.73tn | 49.58k | 133.08 | 1.37 | 12.19 | 2.34 | 32.10 | 32.10 | 2,130.24 | 3,123.56 | 0.3354 | 1.86 | 4.64 | 58,025,380.00 | 0.1843 | 1.36 | 0.2155 | 1.77 | 65.22 | 69.83 | 0.5494 | 3.83 | 0.9382 | 0.4714 | 0.5078 | 226.33 | 18.45 | 4.39 | -41.61 | 0.4586 | 11.30 | 0.00 |
| Bayer AG | 5.28tn | -179.85bn | 8.94tn | 104.71k | -- | 1.53 | 20.75 | 1.69 | -1.53 | -1.30 | 44.69 | 49.29 | 0.3357 | 1.73 | 3.74 | 374,852.60 | -1.14 | 4.12 | -1.39 | 5.28 | 57.42 | 58.83 | -3.39 | 8.16 | 0.8826 | 4.11 | 0.4869 | 69.67 | 13.05 | -0.286 | -47.83 | -11.87 | 3.75 | 6.26 |
| Novartis AG | 5.41tn | 786.99bn | 26.34tn | 109.00k | 30.80 | 4.12 | 18.83 | 4.87 | 3.02 | 4.93 | 20.72 | 22.56 | 0.3829 | 2.21 | 6.04 | 385,292.90 | 5.57 | 6.81 | 7.13 | 8.41 | 70.90 | 66.55 | 14.55 | 17.42 | 0.7283 | 57.90 | 0.3641 | 74.61 | 6.05 | 0.1702 | 65.02 | 6.53 | -0.1366 | 0.9933 |
Data as of Jan 29 2020. Currency figures normalised to Takeda Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
20.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 30 Sep 2019 | 54.77m | 3.47% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 15 Mar 2019 | 53.21m | 3.38% |
| BlackRock Fund Advisorsas of 15 Jan 2019 | 49.61m | 3.15% |
| The Vanguard Group, Inc.as of 09 Oct 2018 | 30.96m | 1.96% |
| Nikko Asset Management Co., Ltd.as of 15 Mar 2019 | 25.19m | 1.60% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2019 | 24.95m | 1.58% |
| State Street Global Advisors Ltd.as of 07 Jan 2019 | 24.73m | 1.57% |
| Mondrian Investment Partners Ltd.as of 08 Jan 2019 | 21.44m | 1.36% |
| Wellington Management Co. LLPas of 08 Jan 2019 | 20.29m | 1.29% |
| Templeton Global Advisors Ltd.as of 30 Nov 2019 | 19.01m | 1.21% |
More ▼
Data from 25 Jul 2019 - 23 Jan 2020Source: FactSet Research Systems Inc.
